Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Based in Bridgewater, New Jersey, Amneal was established in 2002 by brothers Chirag and Chintu Patel with a belief that innovation must be accessible. Our approximately 300 medicines span complex generics, specialty therapies and biosimilars and support over 160 million prescriptions each year, mainly in the U.S. Our businesses include Affordable Medicines; Specialty, with treatments for neurological and endocrine conditions; and AvKARE, which supplies medicines and medical products to federal agencies, retailers and institutions.

AWARDS
  • 2027---Best-Places-to-Work---Badges.png
  • 2026 - Best Places to Work - Badge (1).png
400 Crossing Boulevard, 3rd Floor
Bridgewater, New Jersey 08807
Media Inquiries: MediaRelations@amneal.com
Investor Inquiries: Invest@amneal.com
Corporate Development Inquiries: BusinessDevelopment@amneal.com
Government Inquiries & Business: GovernmentBusiness@amneal.com
Visit our Youtube
NEWS
The list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.
Teams at facilities being developed by Eli Lilly, Regeneron and other companies will receive early technical guidance and additional perks from the FDA.
The takeover will give Amneal control of four facilities to manufacture biosimilars for a planned wave of launches in the coming years.
BioSpace has named 50 life sciences companies to its 2026 Best Places to Work list. AbbVie, Amneal Pharmaceuticals and BridgeBio executives share what makes their organizations special.
Citing insufficient safety evidence for one of the drug’s main ingredients, the regulator in a Complete Response Letter rejected the company’s application for Parkinson’s disease candidate IPX203.
Regeneron envisions new dosing for Eylea’s label and it’s the moment of truth for BioMarin’s gene therapy for hemophilia A. For that and more, see inside.
Between new formulations of traditional drugs nearing the market and completely novel approaches in mid-stage trials, 2023 is poised to be a pivotal year in Parkinson’s disease treatment.
ImmunityBio is laying off 38 employees at its Dunkirk site in New York, Amneal will shutter a Long Island facility and Rigel culls 30 employees following wAIHA regulatory decision.
Amneal Pharmaceuticals received the green light from the U.S. Food and Drug Administration for bevacizumab-maly, a biosimilar to Genentech (Roche)’s Avastin.
IN THE PRESS
JOBS